E-cadherin promoter polymorphisms are not associated with the aggressiveness of prostate cancer in Caucasian patients

Urologic Oncology: Seminars and Original Investigations

Volumn 24, Issue 6, 2006, Pages 496-502

  Li, He Cheng ^a   Albert, Jeffrey M ^b   Shinohara, Eric T ^b   Cai, Qiuyin ^b   Freyer, Andrea ^b   Cai, Hui ^b   Cao, Carolyn ^b   Wang, Zuofei ^b   Kataoka, Nobuhiko ^b   Teng, Ming ^b   Zheng, Wei ^b   Lu, Bo ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Aggressiveness; E cadherin; Polymorphism; Promoter; Prostate cancer

Indexed keywords

DNA; PARAFFIN; PROSTATE SPECIFIC ANTIGEN; UVOMORULIN;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INFILTRATION; CANCER RELAPSE; CAUCASIAN; CHI SQUARE DISTRIBUTION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; ENZYME ASSAY; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GLEASON SCORE; GROUPS BY AGE; HOMOZYGOSITY; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CADHERINS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 33751335434     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2006.02.018     Document Type: Article

References (27)

1. Parkin D.M., Laara E., and Muir C.S. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 41 (1988) 184-197
2. Pisani P., Parkin D.M., Bray F., et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83 (1999) 18-29
3. Parkin D.M., Bray F.I., and Devesa S.S. Cancer burden in the year 2000. The global picture. Eur J Cancer 37 Suppl 8 (2001) S4-S66
4. Quinn M., and Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: International comparisons. BJU Int 90 (2002) 162-173
5. Bostwick D.G., Graham Jr. S.D., Napalkov P., et al. Staging of early prostate cancer: A proposed tumor volume-based prognostic index. Urology 41 (1993) 403-411
6. Zhou W.N., Chen Z.P., You C., et al. Individualized therapy and outcomes of microsurgery, radiotherapy, and chemotherapy for astrocytoma. Ai Zheng 23 Suppl 11 (2004) 1555-1560 [in Chinese]
7. Relling M.V., and Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer 1 (2001) 99-108
8. Efferth T., and Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 107 (2005) 155-176
9. Vleminckx K., Vakaet Jr. L., Mareel M., et al. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66 (1991) 107-119
10. Umbas R., Schalken J.A., Aalders T.W., et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 52 (1992) 5104-5109
11. Umbas R., Isaacs W.B., Bringuier P.P., et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54 (1994) 3929-3933
12. Li L.C., Chui R.M., Sasaki M., et al. A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res 60 (2000) 873-876
13. Shin Y., Kim I.J., Kang H.C., et al. The E-cadherin -347G->GA promoter polymorphism and its effect on transcriptional regulation. Carcinogenesis 25 (2004) 895-899
14. Tsukino H., Kuroda Y., Imai H., et al. Lack of evidence for the association of E-cadherin gene polymorphism with increased risk or progression of prostate cancer. Urol Int 72 (2004) 203-207
15. Verhage B.A., van Houwelingen K., Ruijter T.E., et al. Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer. Int J Cancer 100 (2002) 683-685
16. Shin Y., Kim I.J., Kang H.C., et al. A functional polymorphism (-347 G->GA) in the E-cadherin gene is associated with colorectal cancer. Carcinogenesis 25 (2004) 2173-2176
17. In: Greene F.L., Page D.L., Fleming I.D., et al. (Eds). American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. (2002), Springer, New York (NY) 309-316 Prostate.
18. Loktionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Lett 208 (2004) 1-33
19. Bogenrieder T., and Herlyn M. Axis of evil: Molecular mechanisms of cancer metastasis. Oncogene 22 (2003) 6524-6536
20. Wu M.S., Huang S.P., Chang Y.T., et al. Association of the -160 C -> a promoter polymorphism of E-cadherin gene with gastric carcinoma risk. Cancer 94 (2002) 1443-1448
21. Lei H., Sjoberg-Margolin S., Salahshor S., et al. CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk. Int J Cancer 98 (2002) 199-204
22. Pharoah P.D., Oliveira C., Machado J.C., et al. CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer. Int J Cancer 101 (2002) 196-197
23. Humar B., Graziano F., Cascinu S., et al. Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene 21 (2002) 8192-8195
24. Porter T.R., Richards F.M., Houlston R.S., et al. Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer. Oncogene 21 (2002) 1928-1933
25. Tsukino H., Kuroda Y., Nakao H., et al. E-cadherin gene polymorphism and risk of urothelial cancer. Cancer Lett 195 (2003) 53-58
26. Zhang X., Ma X., Zhu Q.G., et al. Association between a C/A single nucleotide polymorphism of the E-cadherin gene promoter and transitional cell carcinoma of the bladder. J Urol 170 (2003) 1379-1382
27. Nakamura A., Shimazaki T., Kaneko K., et al. Characterization of DNA polymorphisms in the E-cadherin gene (CDH1) promoter region. Mutat Res 502 (2002) 19-24